Pre-operative Trial for Breast Cancer With Nivolumab in Combination With Novel IO
Status:
Recruiting
Trial end date:
2025-01-07
Target enrollment:
Participant gender:
Summary
To determine whether short-term pre-operative nivolumab either as monotherapy or in
combination with low dose doxorubicin or novel IO combinations can induce immune activation
in early BC.